Fiona Barry

1 month ago | pharmaceutical-technology.com | Fiona Barry

The Biosecure Act could still cut off US federal funding to pharma companies that outsource to WuXi AppTec. Geopolitics reportedly had little impact on WuXi AppTec in 2024. Credit: Andy.LIU / Shutterstock. WuXi AppTec (Shanghai, China) has sold off two US/UK businesses in February and March, it revealed in its annual results on 18 March 2025.

2 months ago | mdpi.com | Claudia Ferreira |Fiona Barry |Patrick Sugrue |Miomir Todorović

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jan 17, 2025 | businessandamerica.com | Fiona Barry

WuXi Biologics’ CEO Chris Chen has denied that the company’s sale of its less than four-year-old Ireland site is due to the threat of the US Biosecure Act, and said that the number of new contracts is at an all-time “high”, while speaking at the JP Morgan (JPM) Annual Healthcare Conference 2025 on 15 January.

Jan 16, 2025 | pharmaceutical-technology.com | Fiona Barry

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling effect on clients. At the recent JP Morgan Healthcare Conference 2025, WuXi Biologics’ CEO Chris Chen said the company continues to sign foreign clients and investing in the US, despite political headwinds related to the Biosecure Act.

Jan 15, 2025 | pharmaceutical-technology.com | Fiona Barry

At the JP Morgan Healthcare Conference 2025, Charles River CEO blamed low client spending, loss of a contract and other reasons for lower 2025 projections. Image credit: Shutterstock/ Piotr Swat Charles River Laboratories (CRL) expects its revenue to decline in 2025, the CEO revealed at the JP Morgan Healthcare Conference 2025 in San Francisco on 14 January. The lowered estimate will be along similar lines to projected 2024 revenues. CEO James C.